Pharmacology, Toxicology and Pharmaceutical Science
HIV
100%
Statin (Protein)
60%
Mixed Infection
25%
Human Immunodeficiency Virus Infection
25%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
24%
Prevalence
16%
Influenza Vaccine
16%
Darunavir
16%
Raltegravir
16%
Gilbert Disease
16%
Biological Marker
16%
Tropical Disease
16%
Hepatitis C
16%
Abacavir
16%
Proteinase Inhibitor
16%
Hyperlipidemia
16%
Nicotinic Acid
16%
Thymidine
16%
Skin Disease
16%
Inflammation
16%
Respiratory Tract Disease
16%
Liver Disease
16%
Hepatitis C Virus
16%
Fragility Fracture
16%
Dyslipidemia
13%
All Cause Mortality
11%
Insulin Resistance
10%
Stavudine
8%
Nucleoside Analog
8%
Metabolic Disorder
8%
Lipoatrophy
8%
Viremia
8%
Mortality Rate
8%
RNA Directed DNA Polymerase Inhibitor
8%
Infection
7%
Comorbidity
6%
Liver Cirrhosis
6%
Aminotransferase
6%
Hyperlactatemia
5%
Acetylsalicylic Acid
5%
Medicine and Dentistry
Human Immunodeficiency Virus
44%
Antiretroviral Therapy
36%
Hepatitis C Virus
33%
Mixed Infection
24%
Human Immunodeficiency Virus Infection
24%
Tenofovir
20%
Highly Active Antiretroviral Therapy
19%
Proteinase Inhibitor
16%
Liver Disease
16%
Bone Density
16%
Bone Turnover
16%
Cardiovascular Disease
16%
Thymidine
16%
Raltegravir
16%
Darunavir
16%
Tenofovir/Emtricitabine
16%
Neglected Tropical Diseases
16%
Bone Disease
16%
Sex Hormone
16%
Glucose 6 Phosphate Dehydrogenase
12%
Viremia
11%
Acute Heart Infarction
9%
Somatomedin C
9%
Insulin Resistance
8%
Nucleoside Analogue
8%
Reverse-Transcriptase Inhibitor
8%
Dyslipidemia
8%
Lipoatrophy
8%
Stavudine
8%
Water-Electrolyte Imbalance
8%
Cerebrovascular Disease
8%
Morphology
8%
Hyperlactatemia
5%
All Cause Mortality
5%
Proportional Hazards Model
5%
Virus Replication
5%
Human Immunodeficiency Virus 1 Infection
5%
Platelet
5%
Mortality Rate
5%
Patient Compliance
5%
Osteocalcin
5%
Opportunistic Infection
5%
White Matter Disease
5%
Veterans Health
5%
Hazard Ratio
5%
Keyphrases
HIV Viral Rebound
16%
Abacavir
16%
Darunavir
16%
Influenza Vaccine
16%
Raltegravir
16%
Gilbert Syndrome
16%
Neglected Tropical Diseases
16%
Extended-release Niacin
16%
HIV Clinics
16%
APOBEC3G
16%
APOBEC3F
16%
Statins
16%
Thymidine Analogs
16%
Medically Attended Acute Respiratory Illness
16%
HIV Persistence
16%
Virologically Suppressed
16%
Protease Inhibitors
16%
Antiretroviral Therapy
16%
Central Nervous System Involvement
16%
Osteoporotic Fracture Risk
16%
Statin Use
16%
UGT1A1*28
11%
Alternative Drugs
8%
Antiretroviral
8%
Hyperlactatemia
8%
Stavudine
8%
Metabolic Toxicity
8%
Reverse Transcriptase Inhibitors
8%
Morphological Abnormalities
8%
Metabolic Disturbances
8%
Shape Change
8%
Sustained Viral Suppression
8%
Body Shape
8%
Metabolic Abnormalities
8%
Nucleosides
8%
Standardized Approach
8%
Switch Therapy
8%
Lipoatrophy
8%
Comorbidity
8%
Dyslipidemia
8%
Fat Redistribution
8%
Insulin Resistance
8%
One-component
8%
Myocardial Infarction Disease
7%
Confidence Interval
6%
NRTI-sparing Regimen
5%
Antiretroviral Therapy Initiation
5%
Antiretroviral Adherence
5%
Refill Rate
5%
Low-level Viremia
5%
